Janney Montgomery Scott LLC grew its holdings in shares of MetLife, Inc. (NYSE:MET - Free Report) by 1.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 494,840 shares of the financial services provider's stock after purchasing an additional 5,044 shares during the quarter. Janney Montgomery Scott LLC owned approximately 0.07% of MetLife worth $39,795,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its stake in MetLife by 7.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 26,488,146 shares of the financial services provider's stock worth $2,126,734,000 after buying an additional 1,824,907 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of MetLife by 0.4% in the first quarter. Bank of New York Mellon Corp now owns 8,862,835 shares of the financial services provider's stock worth $711,597,000 after acquiring an additional 36,177 shares during the last quarter. Ameriprise Financial Inc. grew its holdings in MetLife by 3.6% in the first quarter. Ameriprise Financial Inc. now owns 7,406,512 shares of the financial services provider's stock valued at $594,410,000 after purchasing an additional 259,993 shares during the period. Northern Trust Corp increased its position in MetLife by 0.8% during the first quarter. Northern Trust Corp now owns 7,109,423 shares of the financial services provider's stock worth $570,816,000 after purchasing an additional 57,221 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of MetLife by 3.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 6,671,435 shares of the financial services provider's stock worth $535,568,000 after buying an additional 236,698 shares during the last quarter. 94.99% of the stock is currently owned by institutional investors and hedge funds.
MetLife Stock Up 0.4%
Shares of MetLife stock opened at $82.37 on Wednesday. The company has a quick ratio of 0.16, a current ratio of 0.16 and a debt-to-equity ratio of 0.57. The business has a 50-day moving average price of $78.88 and a 200 day moving average price of $78.18. MetLife, Inc. has a fifty-two week low of $65.21 and a fifty-two week high of $89.05. The firm has a market cap of $54.78 billion, a P/E ratio of 13.96, a P/E/G ratio of 0.74 and a beta of 0.87.
MetLife (NYSE:MET - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The financial services provider reported $2.02 earnings per share for the quarter, missing analysts' consensus estimates of $2.32 by ($0.30). The firm had revenue of $17.34 billion during the quarter, compared to the consensus estimate of $18.58 billion. MetLife had a net margin of 5.83% and a return on equity of 19.88%. MetLife's revenue was down 2.7% compared to the same quarter last year. During the same quarter last year, the firm posted $2.28 earnings per share. On average, sell-side analysts forecast that MetLife, Inc. will post 9.65 earnings per share for the current fiscal year.
MetLife Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 5th were given a dividend of $0.5675 per share. This represents a $2.27 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend was Tuesday, August 5th. MetLife's dividend payout ratio is currently 38.47%.
Wall Street Analysts Forecast Growth
MET has been the subject of a number of research reports. Morgan Stanley lowered their price target on MetLife from $98.00 to $94.00 and set an "overweight" rating for the company in a research report on Monday, August 18th. Cowen reiterated a "buy" rating on shares of MetLife in a report on Friday, August 22nd. Wells Fargo & Company restated an "overweight" rating and issued a $97.00 price target (up previously from $94.00) on shares of MetLife in a report on Thursday, July 10th. UBS Group reduced their price target on shares of MetLife from $94.00 to $91.00 and set a "buy" rating on the stock in a research report on Thursday, August 7th. Finally, Barclays increased their price objective on shares of MetLife from $88.00 to $94.00 and gave the stock an "overweight" rating in a research report on Monday, July 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat, MetLife currently has an average rating of "Moderate Buy" and an average price target of $94.64.
Check Out Our Latest Stock Analysis on MetLife
MetLife Company Profile
(
Free Report)
MetLife, Inc, a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through six segments: Retirement and Income Solutions; Group Benefits; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements.
Further Reading
Want to see what other hedge funds are holding MET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MetLife, Inc. (NYSE:MET - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MetLife, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MetLife wasn't on the list.
While MetLife currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.